Phenotypes associated with this allele

• Allele Symbol: Runx1⁺
• Allele Name: wild type
• Allele ID: MGI:1857581
• Summary: 20 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Runx1^tm2.1(Runx1/Mecom)Homy/Runx1^+	B6.129P2-Runx1^tm2.1(Runx1/Mecom)Homy	MGI:4835667
ht2	Runx1^tm1Spe/Runx1^+	either: (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA/Ca) or (involves: 129S4/SvJae * C57BL/6 * CBA/Ca)	MGI:2655966
ht3	Runx1^tm1Spe/Runx1^+	either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6)	MGI:3709771
ht4	Runx1^tm1(cre/Esr1*)Ims/Runx1^+	either: (involves: C57BL/6 * CBA) or (involves: C57BL/6 * CBA * ICR)	MGI:3712087
ht5	Runx1^tm2Dow/Runx1^+	involves: 129P2/OlaHsd * C57BL/6	MGI:2667307
ht6	Runx1^tm1Dow/Runx1^+	involves: 129P2/OlaHsd * C57BL/6	MGI:2665509
ht7	Runx1^tm1Dez/Runx1^+	involves: 129S4/SvJae * C57BL/6	MGI:2665855
ht8	Runx1^tm8Spe/Runx1^+	involves: 129/Sv * C57BL/6	MGI:3709731
ht9	Runx1^tm4Spe/Runx1^+	involves: 129/Sv * C57BL/6	MGI:3709727
ht10	Runx1^tm5Spe/Runx1^+	involves: 129/Sv * C57BL/6	MGI:3709728
ht11	Runx1^tm6Spe/Runx1^+	involves: 129/Sv * C57BL/6	MGI:3709729
ht12	Runx1^tm7Spe/Runx1^+	involves: 129/Sv * C57BL/6	MGI:3709730
ht13	Runx1^tm1(RUNX1/EVI1)Kmit/Runx1^+	involves: C57BL/6 * CBA	MGI:3701994
cn14	Runx1^tm1Toku/Runx1^+ Runx3^tm1Itan/Runx3^tm1Itan Tg(Cd4-cre)1Cwi/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:3776110
cn15	Etv6^tm1(RUNX1)Haho/Etv6^+ Runx1^tm3Spe/Runx1^+ Tg(Mx1-cre)1Cgn/0	involves: 129S1/Sv * 129S4/SvJae * C57BL/6 * CBA	MGI:4356086
cn16	Hip1^tm4Tsr/Hip1^+ Runx1^tm3Dow/Runx1^+ Tg(Mx1-cre)1Cgn/0	involves: 129X1/SvJ * C57BL/6 * CBA	MGI:4356330
cn17	Bcr^tm1(BCR/ABL)Tsr/Bcr^+ Runx1^tm3Dow/Runx1^+ Tg(Vav1-cre)#Cgp/0	involves: C57BL/6	MGI:5525100
cn18	Runx1^tm3Dow/Runx1^+ Tg(Mx1-cre)1Cgn/0	involves: C57BL/6 * CBA	MGI:3814543
cn19	Runx1t1^tm1Buch/Runx1t1^+ Runx1^tm1Buch/Runx1^+ Tg(Nes-cre)1Atp/0	involves: FVB/N	MGI:2671931
cx20	Runx1^tm1Yg/Runx1^+ Tg(Runx1-GFP)#Itan/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:4459014

Genotype
MGI:4835667

ht1

• Allelic Composition: Runx1^{tm2.1(Runx1/Mecom)Homy}/Runx1⁺
• Genetic Background: B6.129P2-Runx1^{tm2.1(Runx1/Mecom)Homy}

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:164806 )

• unlike mice heterozygous for Runx1^{tm1(RUNX1/EVI1)Kmit} heterozygotes are viable with no gross abnormalities and normal hematopoietic parameters

Genotype
MGI:2655966

ht2

• Allelic Composition: Runx1^tm1Spe/Runx1⁺
• Genetic Background: either: (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA/Ca) or (involves: 129S4/SvJae * C57BL/6 * CBA/Ca)

neoplasm

increased T cell derived lymphoma incidence ( J:80829 )

• survival of mutants shows slight but significant increase compared to transgenic mice on a wild-type Runx1 background

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:80829 )

• survival of mutants shows slight but significant increase compared to transgenic mice on a wild-type Runx1 background

immune system

increased T cell derived lymphoma incidence ( J:80829 )

• survival of mutants shows slight but significant increase compared to transgenic mice on a wild-type Runx1 background

hematopoietic system

increased T cell derived lymphoma incidence ( J:80829 )

• survival of mutants shows slight but significant increase compared to transgenic mice on a wild-type Runx1 background

Genotype
MGI:3709771

ht3

• Allelic Composition: Runx1^tm1Spe/Runx1⁺
• Genetic Background: either: (involves: 129S4/SvJae * BALB/c) or (involves: 129S4/SvJae * C57BL/6)

neoplasm

neoplasm ( J:80829 )

N • mice infected with Moloney murine leukemia virus within 24 hours of birth do not show any increase in tumor incidence or latency compared to infected littermate controls

embryo

abnormal embryonic hematopoiesis ( J:120100 )

• at E11.5, animals have a >3-fold decrease in CFU-C in AGM (aorta/gonad/mesonephros) regions than wild-type embryos in the AGM region

hematopoietic system

abnormal embryonic hematopoiesis ( J:120100 )

• at E11.5, animals have a >3-fold decrease in CFU-C in AGM (aorta/gonad/mesonephros) regions than wild-type embryos in the AGM region

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• a significant decrease in percentage of CD4+ splenic T cells and in the CD4+:CD8+ ratio is observed compared to wild-type adults, but percentage of CD8+ T cells is not changed

immune system

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• a significant decrease in percentage of CD4+ splenic T cells and in the CD4+:CD8+ ratio is observed compared to wild-type adults, but percentage of CD8+ T cells is not changed

Genotype
MGI:3712087

ht4

• Allelic Composition: Runx1^{tm1(cre/Esr1*)Ims}/Runx1⁺
• Genetic Background: either: (involves: C57BL/6 * CBA) or (involves: C57BL/6 * CBA * ICR)

hematopoietic system

hematopoietic system phenotype ( J:121435 )

N • heterozygotes appear normal, with no observable defects in hematopoietic system development

Genotype
MGI:2667307

ht5

• Allelic Composition: Runx1^tm2Dow/Runx1⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:79160 )

• death at approximately E13.5

cardiovascular system

hemopericardium ( J:79160 )

• evident at E12.5

intraventricular hemorrhage ( J:79160 )

• evident at E12.5

hematopoietic system

abnormal embryonic hematopoiesis ( J:79160 )

• failure of embryonic hematopoiesis

liver/biliary system

pale liver ( J:79160 )

• evident at E12.5

nervous system

intraventricular hemorrhage ( J:79160 )

• evident at E12.5

homeostasis/metabolism

hemopericardium ( J:79160 )

• evident at E12.5

embryo

abnormal embryonic hematopoiesis ( J:79160 )

• failure of embryonic hematopoiesis

Genotype
MGI:2665509

ht6

• Allelic Composition: Runx1^tm1Dow/Runx1⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

normal phenotype

no abnormal phenotype detected ( J:31130 )

• viable and overtly normal, with normal hematocrits, white blood cell differentials, nucleated blood cell count, and distribution of peripheral blood lymphocyte subsets

Genotype
MGI:2665855

ht7

• Allelic Composition: Runx1^tm1Dez/Runx1⁺
• Genetic Background: involves: 129S4/SvJae * C57BL/6

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:38705 )

• death between E12.5 and E13.5

cardiovascular system

hemorrhage ( J:38705 )

• evident at E13.5 in the CNS, the VII/VIII cranial nerve complex and intersegmental regions along the presumptive spinal column

hematopoietic system

impaired hematopoiesis ( J:38705 )

• embryonic liver

Genotype
MGI:3709731

ht8

• Allelic Composition: Runx1^tm8Spe/Runx1⁺
• Genetic Background: involves: 129/Sv * C57BL/6

embryo

abnormal embryonic hematopoiesis ( J:120100 )

• fetal liver CFU-C numbers are significantly higher than in Runx1^tm1Spe/+ fetuses

hematopoietic system

abnormal embryonic hematopoiesis ( J:120100 )

• fetal liver CFU-C numbers are significantly higher than in Runx1^tm1Spe/+ fetuses

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• a significant decrease in percentage of CD4+ splenic T cells, and in the CD4+:CD8+ ratio is observed compared to wild-type adults, but percentage of CD8+ T cells is not changed

immune system

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• a significant decrease in percentage of CD4+ splenic T cells, and in the CD4+:CD8+ ratio is observed compared to wild-type adults, but percentage of CD8+ T cells is not changed

Genotype
MGI:3709727

ht9

• Allelic Composition: Runx1^tm4Spe/Runx1⁺
• Genetic Background: involves: 129/Sv * C57BL/6

embryo

abnormal embryonic hematopoiesis ( J:120100 )

• aorta/gonad/mesonephros (AGM) regions have significantly more CFU-C than those in Runx1^tm1Spe/+ fetuses

• fetal liver CFU-C numbers are significantly higher than in Runx1^tm1Spe/+ fetuses

hematopoietic system

abnormal embryonic hematopoiesis ( J:120100 )

• aorta/gonad/mesonephros (AGM) regions have significantly more CFU-C than those in Runx1^tm1Spe/+ fetuses

• fetal liver CFU-C numbers are significantly higher than in Runx1^tm1Spe/+ fetuses

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• a significant decrease in percentage of CD4+ splenic T cells, and in the CD4+:CD8+ ratio is observed compared to wild-type adults, but percentage of CD8+ T cells is not changed

immune system

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• a significant decrease in percentage of CD4+ splenic T cells, and in the CD4+:CD8+ ratio is observed compared to wild-type adults, but percentage of CD8+ T cells is not changed

Genotype
MGI:3709728

ht10

• Allelic Composition: Runx1^tm5Spe/Runx1⁺
• Genetic Background: involves: 129/Sv * C57BL/6

embryo

abnormal embryonic hematopoiesis ( J:120100 )

• at E11.5, numbers of CFU-C is reduced slightly more than in Runx1^tm1Spe/+ fetuses but is significantly less than in Runx1^tm6Spe/+ fetuses

hematopoietic system

abnormal embryonic hematopoiesis ( J:120100 )

• at E11.5, numbers of CFU-C is reduced slightly more than in Runx1^tm1Spe/+ fetuses but is significantly less than in Runx1^tm6Spe/+ fetuses

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• animals have a smaller percentage of CD4+ cells and a lower CD4+:CD8+ ratio than Runx1^tm1Spe/+ adults

immune system

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• animals have a smaller percentage of CD4+ cells and a lower CD4+:CD8+ ratio than Runx1^tm1Spe/+ adults

Genotype
MGI:3709729

ht11

• Allelic Composition: Runx1^tm6Spe/Runx1⁺
• Genetic Background: involves: 129/Sv * C57BL/6

embryo

abnormal embryonic hematopoiesis ( J:120100 )

• aorta/gonad/mesonephros (AGM) regions have significantly more CFU-C than those in Runx1^tm1Spe/+ fetuses

hematopoietic system

abnormal embryonic hematopoiesis ( J:120100 )

• aorta/gonad/mesonephros (AGM) regions have significantly more CFU-C than those in Runx1^tm1Spe/+ fetuses

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• a significant decrease in percentage of CD4+ splenic T cells, and in the CD4+:CD8+ ratio is observed compared to wild-type adults, but percentage of CD8+ T cells is not changed

immune system

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• a significant decrease in percentage of CD4+ splenic T cells, and in the CD4+:CD8+ ratio is observed compared to wild-type adults, but percentage of CD8+ T cells is not changed

Genotype
MGI:3709730

ht12

• Allelic Composition: Runx1^tm7Spe/Runx1⁺
• Genetic Background: involves: 129/Sv * C57BL/6

embryo

abnormal embryonic hematopoiesis ( J:120100 )

hematopoietic system

abnormal embryonic hematopoiesis ( J:120100 )

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• a significant decrease in percentage of CD4+ splenic T cells, and in the CD4+:CD8+ ratio is observed compared to wild-type adults, but percentage of CD8+ T cells is not changed

immune system

decreased CD4-positive, alpha-beta T cell number ( J:120100 )

• a significant decrease in percentage of CD4+ splenic T cells, and in the CD4+:CD8+ ratio is observed compared to wild-type adults, but percentage of CD8+ T cells is not changed

Genotype
MGI:3701994

ht13

• Allelic Composition: Runx1^{tm1(RUNX1/EVI1)Kmit}/Runx1⁺
• Genetic Background: involves: C57BL/6 * CBA

mortality/aging

embryonic lethality during organogenesis, complete penetrance ( J:118892 )

• at E10.5, 10% of embryos are found dead while at E14.5, all mutant heterozygotes are dead; data indicates embryos die ~E13.5 from CNS hemorrhage

embryo

abnormal embryonic hematopoiesis ( J:118892 )

• liver at E12.5 shows near complete absence of erythroid, myeloid, or megakaryocytic progenitors

• cultured E12.5 fetal liver cells give rise only to macrophage colonies whereas wild-type cells produce multilineage colonies; E13.5 cells give rise to numerous mixed-like colonies

hematopoietic system

abnormal embryonic hematopoiesis ( J:118892 )

• liver at E12.5 shows near complete absence of erythroid, myeloid, or megakaryocytic progenitors

• cultured E12.5 fetal liver cells give rise only to macrophage colonies whereas wild-type cells produce multilineage colonies; E13.5 cells give rise to numerous mixed-like colonies

abnormal myelopoiesis ( J:118892 )

• postenucleated erythrocytes are absent from peripheral blood of mutant embryos, but are present in wild-type littermates

abnormal megakaryocyte morphology ( J:118892 )

decreased erythrocyte cell number ( J:118892 )

immune system

abnormal myelopoiesis ( J:118892 )

• postenucleated erythrocytes are absent from peripheral blood of mutant embryos, but are present in wild-type littermates

cardiovascular system

intraventricular hemorrhage ( J:118892 )

• hemorrhage occurs as early as E12.5 in the cerebral ventricle, as well as the dorsal root ganglia

nervous system

intraventricular hemorrhage ( J:118892 )

• hemorrhage occurs as early as E12.5 in the cerebral ventricle, as well as the dorsal root ganglia

Genotype
MGI:3776110

cn14

• Allelic Composition: Runx1^tm1Toku/Runx1⁺; Runx3^tm1Itan/Runx3^tm1Itan; Tg(Cd4-cre)1Cwi/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2

immune system

decreased CD8-positive, alpha-beta T cell number ( J:131081 )

• significantly lower than in controls

hematopoietic system

decreased CD8-positive, alpha-beta T cell number ( J:131081 )

• significantly lower than in controls

Genotype
MGI:4356086

cn15

• Allelic Composition: Etv6^{tm1(RUNX1)Haho}/Etv6⁺; Runx1^tm3Spe/Runx1⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S1/Sv * 129S4/SvJae * C57BL/6 * CBA

hematopoietic system

increased hematopoietic stem cell number ( J:151639 )

• following treatment with pIpC, the number of progenitors, enriched hematopoietic stem cells, and pure hematopoietic stem cells are increased compared to similarly treated wild-type mice

Genotype
MGI:4356330

cn16

• Allelic Composition: Hip1^tm4Tsr/Hip1⁺; Runx1^tm3Dow/Runx1⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129X1/SvJ * C57BL/6 * CBA

mortality/aging

postnatal lethality ( J:151974 )

• fewer than expected mice are present at weaning

hematopoietic system

abnormal definitive hematopoiesis ( J:151974 )

• bone marrow cells from pIpC-induced mice form fewer granulocyte-macrophage positive colonies than when wild-type cells are used

• bone marrow cells transplanted into wild-type mice and induced with pIpC fail to reconstitute multiple hematopoietic lineages

• however, treatment with imatinib restores the ability of pIpC-treated bone marrow cells to induce long-term multiple lineages reconstitution in transplantation experiments

decreased common myeloid progenitor cell number ( J:151974 )

• bone marrow cells from pIpC-induced mice form fewer granulocyte, erythrocyte, macrophage, and megakaryocyte positive colonies than when wild-type cells are used

abnormal myelopoiesis ( J:151974 )

• all pIpC-induced mice develop a chronic myelocytic leukemia (CML)-like myeloproliferative disease

• bone marrow cells activated with pIpC induce develop a CML-like myeloproliferative disease when transplanted into wild-type mice

• however, secondary transplantation of neoplastic cells or fractionated splenocytes are highly inefficient at inducing myeloproliferative disease

extramedullary hematopoiesis ( J:151974 )

• in pIpC-induced mice

abnormal bone marrow cell morphology/development ( J:151974 )

• 2 weeks after pIpC induction, bone marrow and spleens exhibit a decreased in the frequency of lymphoid and erythroid lineages but an increase in myeloid lineages compared to control mice

decreased bone marrow cell number ( J:151974 )

• in pIpC-induced mice despite treatment with imatinib

increased leukocyte cell number ( J:151974 )

• after pIpC induction, mice exhibit severe myeloid leukocytosis with a 25-fold increase in white blood cells compared with similarly treated wild-type mice

• however, treatment with imatinib reduces white blood cell counts to wild-type levels

increased granulocyte number ( J:151974 )

• the number of Mac1+Gr1+ myeloid cells in the spleen and bone marrow of pIpC-induced mice is increased compared to in wild-type mice

increased neutrophil cell number ( J:151974 )

• severe following pIpC induction

decreased hematopoietic stem cell number ( J:151974 )

• the frequency of hematopoietic stem cells in the bone marrow of pIpC-induced mice is decreased compared to in wild-type mice

• the number of hematopoietic stem cells in the bone marrow of pIpC-induced mice is less than in wild-type mice

• bone marrow cells transplanted into wild-type mice and activated with pIpC inhibit normal bone marrow hematopoietic stem cells and result in a decrease in donor and recipient-type hematopoietic stem cells compared to when wild-type bone marrow cells are transplanted

• however, treatment of pIpC-induced mice with imatinib returns the frequency of hematopoietic stem cell to near normal even in transplantation experiments

increased hematopoietic stem cell number ( J:151974 )

• the absolute number of hematopoietic stem cells in the spleen is increased in pIpC-induced mice compared to in wild-type mice

abnormal spleen morphology ( J:151974 )

• pIpC-induced mice exhibit splenic architecture effacement unlike similarly treated wild-type mice

• however, treatment with imatinib returns spleen architecture to normal

• 2 weeks after pIpC induction, bone marrow and spleens exhibit a decreased in the frequency of lymphoid and erythroid lineages but an increase in myeloid lineages compared to control mice

enlarged spleen ( J:151974 )

• 10-fold 72 hours after pIpC induction unlike similarly treated wild-type mice

• however, treatment with imatinib reduces liver size to wild-type and clears neoplastic cells

increased spleen weight ( J:151974 )

• following pIpC induction

spleen hyperplasia ( J:151974 )

• in pIpC-induced mice

increased spleen red pulp amount ( J:151974 )

• in pIpC-induced mice

abnormal spleen B cell follicle morphology ( J:151974 )

• pIpC-induced mice loss organized splenic follicle cells unlike similarly treated wild-type mice

abnormal bone marrow cell physiology ( J:151974 )

• when bone marrow cells are transplanted into recipient mice and induced with pIpC recipient mice exhibit enlarge spleen, effacement of spleen architecture, and increased white blood cell counts compared to when mice are transplanted with control bone marrow cells lacking the cre transgene

• however, treatment with imatinib decreased white blood cell counts in recipients following pIpC-induction of transplanted bone marrow cells

• bone marrow cells transplanted into wild-type mice and activated with pIpC inhibit normal bone marrow hematopoietic stem cells and result in a decrease in donor and recipient-type hematopoietic stem cells compared to when wild-type bone marrow cells are transplanted

neoplasm

abnormal tumor morphology ( J:151974 )

• neoplastic cells in the livers and spleens of pIpC-induced mice are positive for proliferative markers

increased chronic myelocytic leukemia incidence ( J:151974 )

• 25% of un-induced mice develop a chronic myelocytic leukemia (CML)-like disease unlike control mice

• pIpC-induced mice exhibit a CML-like myeloproliferative disease unlike similarly treated wild-type mice

• bone marrow cells activated with pIpC induce develop a CML-like myeloproliferative disease when transplanted into wild-type mice

• however, secondary transplantation of neoplastic cells or fractionated splenocytes are highly inefficient at inducing myeloproliferative disease

• treatment with imatinib increases the frequency of leukemia initiating cells in transplantation experiments with pIpC-activated whole bone marrow cells and hematopoietic stem cells and results in greater incidence of CML-like disease

• leukemia cells infiltrate the lungs in pIpC-induced mice

liver/biliary system

abnormal liver morphology ( J:151974 )

• pIpC-induced mice exhibit mature myeloid cells surrounding portal cavities and infiltrating the parenchyme unlike in similarly treated wild-type mice

enlarged liver ( J:151974 )

• 2-fold 72 hours after pIpC induction unlike similarly treated wild-type mice

• however, treatment with imatinib reduces liver size to wild-type and clears neoplastic cells

increased liver weight ( J:151974 )

• following pIpC induction

abnormal liver parenchyma morphology ( J:151974 )

• pIpC-induced mice exhibit mature myeloid cells infiltrating the parenchyme unlike in similarly treated wild-type mice

respiratory system

abnormal lung morphology ( J:151974 )

• pIpC-induced mice exhibit mature myeloid cells infiltrating the lungs unlike in similarly treated wild-type mice

• leukemia cells infiltrate the lungs in pIpC-induced mice

immune system

abnormal myelopoiesis ( J:151974 )

• all pIpC-induced mice develop a chronic myelocytic leukemia (CML)-like myeloproliferative disease

• bone marrow cells activated with pIpC induce develop a CML-like myeloproliferative disease when transplanted into wild-type mice

• however, secondary transplantation of neoplastic cells or fractionated splenocytes are highly inefficient at inducing myeloproliferative disease

increased leukocyte cell number ( J:151974 )

• after pIpC induction, mice exhibit severe myeloid leukocytosis with a 25-fold increase in white blood cells compared with similarly treated wild-type mice

• however, treatment with imatinib reduces white blood cell counts to wild-type levels

increased granulocyte number ( J:151974 )

• the number of Mac1+Gr1+ myeloid cells in the spleen and bone marrow of pIpC-induced mice is increased compared to in wild-type mice

increased neutrophil cell number ( J:151974 )

• severe following pIpC induction

abnormal spleen morphology ( J:151974 )

• pIpC-induced mice exhibit splenic architecture effacement unlike similarly treated wild-type mice

• however, treatment with imatinib returns spleen architecture to normal

• 2 weeks after pIpC induction, bone marrow and spleens exhibit a decreased in the frequency of lymphoid and erythroid lineages but an increase in myeloid lineages compared to control mice

enlarged spleen ( J:151974 )

• 10-fold 72 hours after pIpC induction unlike similarly treated wild-type mice

• however, treatment with imatinib reduces liver size to wild-type and clears neoplastic cells

increased spleen weight ( J:151974 )

• following pIpC induction

spleen hyperplasia ( J:151974 )

• in pIpC-induced mice

increased spleen red pulp amount ( J:151974 )

• in pIpC-induced mice

abnormal spleen B cell follicle morphology ( J:151974 )

• pIpC-induced mice loss organized splenic follicle cells unlike similarly treated wild-type mice

growth/size/body

enlarged liver ( J:151974 )

• 2-fold 72 hours after pIpC induction unlike similarly treated wild-type mice

• however, treatment with imatinib reduces liver size to wild-type and clears neoplastic cells

increased liver weight ( J:151974 )

• following pIpC induction

enlarged spleen ( J:151974 )

• 10-fold 72 hours after pIpC induction unlike similarly treated wild-type mice

• however, treatment with imatinib reduces liver size to wild-type and clears neoplastic cells

increased spleen weight ( J:151974 )

• following pIpC induction

spleen hyperplasia ( J:151974 )

• in pIpC-induced mice

Genotype
MGI:5525100

cn17

• Allelic Composition: Bcr^{tm1(BCR/ABL)Tsr}/Bcr⁺; Runx1^tm3Dow/Runx1⁺; Tg(Vav1-cre)#Cgp/0
• Genetic Background: involves: C57BL/6

mortality/aging

premature death ( J:203111 )

• 50% of mice die between 6-12 months of age

hematopoietic system

increased neutrophil cell number ( J:203111 )

• prior to death mice exhibit neutrophilia and/or moncytosis

thrombocytopenia ( J:203111 )

• prior to death mice exhibit thrombocytopenia

decreased lymphocyte cell number ( J:203111 )

• prior to death mice exhibit lymphopenia

increased monocyte cell number ( J:203111 )

• prior to death mice exhibit neutrophilia and/or moncytosis

immune system

increased neutrophil cell number ( J:203111 )

• prior to death mice exhibit neutrophilia and/or moncytosis

decreased lymphocyte cell number ( J:203111 )

• prior to death mice exhibit lymphopenia

increased monocyte cell number ( J:203111 )

• prior to death mice exhibit neutrophilia and/or moncytosis

Genotype
MGI:3814543

cn18

• Allelic Composition: Runx1^tm3Dow/Runx1⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: C57BL/6 * CBA

mortality/aging

decreased tumor-free survival time ( J:77129 )

• mice treated with pI:pC and ENU die rapidly between 2 and 10 months coincident with tumor presentation

neoplasm

increased tumor incidence ( J:77129 )

• 47% of 5-10 week old mice treated with pI:pC then treated with ENU develop hematopoietic neoplasms 2-10 months after treatment

increased T cell derived lymphoma incidence ( J:77129 )

• some pI:pC and ENU treated mice develop thymic derived T cell lymphoblastic lymphomas (17%)

increased acute promyelocytic leukemia incidence ( J:77129 )

• some pI:pC and ENU treated mice develop granulocytic sarcoma/acute myeloid leukemia (30%)

increased sarcoma incidence ( J:77129 )

• some pI:pC and ENU treated mice develop granulocytic sarcoma/acute myeloid leukemia (30%); these are solid masses of proliferating myeloblasts which form in retroperitoneum, soft tissue, or in bones of sternum, cranium, or extremities adjacent to soft tissue

• tumor cells disseminate widely, with clusters of cells found in spleen, liver, kidney and lymph nodes

• in some mice, increased myeloblasts are observed in bone marrow, as well as markedly increased white blood cell counts with identifiable circulating leukemic blasts

• tumors are transplantable

endocrine/exocrine glands

increased T cell derived lymphoma incidence ( J:77129 )

• some pI:pC and ENU treated mice develop thymic derived T cell lymphoblastic lymphomas (17%)

hematopoietic system

hematopoietic system phenotype ( J:77129 )

N • mimimal abnormalities in hematopoiesis are observed in mutants expressing the Runx1 knock-in allele after pI:pC treatment, although a slight increase in granulocyte-monocyte, mixed and total colonies, as well as in day 12 CFUs in bone marrow, is seen

N • no leukemia develops during the first 11months of life of treated mutants

abnormal hematopoietic system morphology/development ( J:77129 )

• 2 mice develop hematopoietic neoplasms by 1 year of age (1 T cell lymphoma, 1 undifferentiated lymphoma)

increased T cell derived lymphoma incidence ( J:77129 )

• some pI:pC and ENU treated mice develop thymic derived T cell lymphoblastic lymphomas (17%)

cellular

abnormal cell physiology ( J:77129 )

• bone marrow cells isolated from mice treated with pI:pC show enhanced replating efficiency in culture; cells are able to form myeloid colonies long after wild-type cells have stopped growing

immune system

increased T cell derived lymphoma incidence ( J:77129 )

• some pI:pC and ENU treated mice develop thymic derived T cell lymphoblastic lymphomas (17%)

Genotype
MGI:2671931

cn19

• Allelic Composition: Runx1t1^tm1Buch/Runx1t1⁺; Runx1^tm1Buch/Runx1⁺; Tg(Nes-cre)1Atp/0
• Genetic Background: involves: FVB/N

normal phenotype

no abnormal phenotype detected ( J:68499 )

• mice were viable and showed no malignancies within 5 months of birth

Genotype
MGI:4459014

cx20

• Allelic Composition: Runx1^tm1Yg/Runx1⁺; Tg(Runx1-GFP)#Itan/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

cardiovascular system

abnormal dorsal aorta morphology ( J:160791 )

• mice exhibit fewer large GFP+ hematopoietic cells or clusters in the dorsal aorta compared with Tg(Runx1-GFP)#Itan mice

hematopoietic system

abnormal hematopoietic system morphology/development ( J:160791 )

• mice exhibit fewer large GFP+ hematopoietic cells or clusters in the dorsal aorta compared with Tg(Runx1-GFP)#Itan mice